Navigation Links
Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
Date:11/7/2011

wn as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's ENHANZE™ Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. In addition to partnerships that use Halozyme's ENHANZE™ Technology, the Company has a number of product candidates in its pipeline that target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the commercial reintroduction of Hylenex, the timing, scope and outcomes of our clinical trials and presentation of data from our clinical trials, future regulatory submissions and PDUFA dates for our product candidates, expected financial results including anticipated operating expenses and net cash burn for FY 2011 as well as expected activities under our collaborative partnerships that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including clinical trial results, regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

Halozyme Contact
Kurt Gustafson
Chief Financial Offi
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
2. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
3. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
4. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
5. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
6. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
7. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
8. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
9. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
10. Halozyme Receives $5.5 Million Payment From Baxter
11. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 SRI International has been ... National Institute of Allergy and Infectious Diseases (NIAID), part ... development of potential therapies for HIV infection and AIDS. ... HIV and AIDS and the complications and opportunistic infections ... preventing sexual transmission of HIV. According ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 Three ... be semi-finalists in Livestrong’s Big C Competition. Out of ... are each headed to the semi-final round. In this ... exclusive three-month accelerator program, complete with mentoring from thought-leaders ... , As part of the angelMD commitment to the ...
(Date:7/24/2014)... July 24, 2014  Neogen Corporation (Nasdaq: ... of its potential revenue from new rodenticide research are ... and analysts on July 22, 2014, Neogen,s CEO commented ... this research. "It was my intent Tuesday ... potential of a new type of rodenticide, but certainly ...
(Date:7/24/2014)... 1000 balances – 4 steps – ... weighing needs and expertly narrows down the mass of ... or even terminals. , First, select the working ... select readability instead) and define the accuracy – it’s ... narrows down the list to models that fit best ...
Breaking Biology Technology:National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2
... ... Prize in Chemistry published papers on their award-winning work based on data collected at the ... ... Nobel Prize in Chemistry published papers on their award-winning work based on data collected at ...
... Inc. (Nasdaq: LXRX ) today announced that it ... conditions, 27,500,000 shares of its common stock pursuant to ... are being offered through the underwriters and 11,087,387 shares ... Lexicon also intends to grant the underwriters a ...
... ... President Obama , ... Argonne, Ill. (Vocus) October 7, 2009 -- The IBM Blue Gene series of energy-efficient ... President Barack Obama as a Medal of Technology and Innovation award-winner on October 7 ...
Cached Biology Technology:Argonne's Advanced Photon Source Lit the Way to Chemistry Nobel 2Argonne's Advanced Photon Source Lit the Way to Chemistry Nobel 3Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock 2Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock 3DOE Labs Take Pride in Award-Winning IBM Blue Gene Series 2DOE Labs Take Pride in Award-Winning IBM Blue Gene Series 3DOE Labs Take Pride in Award-Winning IBM Blue Gene Series 4
(Date:7/24/2014)... 2014) Scientists at The New York Stem ... closer to creating a viable cell replacement therapy ... , For the first time, NYSCF scientists ... skin samples of patients with primary progressive multiple ... to induce these stem cells into becoming oligodendrocytes, ...
(Date:7/24/2014)... 24, 2014) Scientists at The New York ... step closer to creating a viable cell replacement ... cells. , For the first time, NYSCF ... from skin samples of patients with primary progressive ... protocol to induce these stem cells into becoming ...
(Date:7/24/2014)... two factors that characterize sustainable university and college ... qualified physics teachers. Specifically, one or more faculty ... in combination with institutional motivation and commitment can ... Engineering and Math (STEM) teacher shortages are especially ... way for institutions seeking to increase the number ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Creating sustainable STEM teacher preparation programs 2
... Mich. --- Scientists have discovered a molecular process in ... a target for treatments to prevent or reverse addiction ... of Neuroscience , Michigan State University neuroscientist A.J. Robison ... brain,s pleasure center that responds to stimuli such as ...
... can literally be the difference between life and death. ... stood out starkly against the light-colored, sandy soil, making them ... the mice evolved a new system of camouflage lighter ... in the extent of pigment across their body that ...
... Pilot whales that have died in mass strandings ... at each event, a new study concludes, challenging a ... beach and to almost certain death because of familial ... strandings, scientists have determined that both related and unrelated ...
Cached Biology News:Discovery could yield treatment for cocaine addicts 2One gene, many mutations 2One gene, many mutations 3Study questions the role of kinship in mass strandings of pilot whales 2Study questions the role of kinship in mass strandings of pilot whales 3
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
Rabbit Polyclonal antibody to Perilipin Applications: This antibody is useful for Western blot anlaysis where a band at ~60 kDa is seen....
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
... designer enzyme that enables RT-PCR in ... enzyme allows reverse transcription and PCR ... temperatures (65C), which helps to remove ... results in highly stringent, accurate annealing ...
Biology Products: